| Date | Title | Description |
| 21.03.2024 | Eisbach Raises $4.5M from Cancer Focus Fund | Eisbach, a Martinsried, Germany-based clinical-stage biotechnology company, received $4.5M from Cancer Focus Fund.
The company intends to use the funds to to support a Phase 1/2 clinical trial of its lead candidate, EIS-12656, which will be... |
| 20.06.2023 | Biotech Breakthroughs: Unraveling Germany’s 15 Emerging Biotechnology Startups | Emergence Therapeutics led by Jack Elands, is a promising biopharmaceutical company dedicated to advancing novel ADC immunotherapies to address cancers with high unmet needs.
Table of Contents show
1 FaCellitate – Supporting Drug Discover... |
| 07.07.2021 | Eisbach Bio Receives EUR 8 Million Government Grant to Progress COVID-19 Antiviral Through Phase I/II Clinical Development | MUNICH, Germany, July 7, 2021 – Eisbach Bio, a biotechnology company targeting the molecular machines that drive human disease, today announced additional financial support from the German Ministry for Education and Research (BMBF) for the ... |
| 07.07.2021 | Press Release : Eisbach Bio Receives EUR 8 Million Government Grant to Progress COVID-19 Antiviral Through Phase I/II Clinical Development | MUNICH, Germany, July 7, 2021 -- Eisbach Bio https://www.globenewswire.com/Tracker?data=zQBFtv49l9XZ0pTXjbmF7RirhWLKqufSkOBbGYydMhTxATGDffODr2cdmPW0tMlPLVEpe-OwYZLznUJqnQEV_Q== , a biotechnology company targeting the molecular machines that... |
| - | Eisbach Bio | “Eisbach Bio – Targeting Synthetic Lethality in Cancer” |
